

#3113; P#9831

RECEIVED

OCT 15 1998

GROUP 180

SRL 6067
PATENT

#50
G#0
16/4



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gary S. JACOB et al.

Group Art Unit 1614

Application Number: 09/023,401

Filed: February 12, 1998

For: USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
COMPOUNDS IN COMBINATION THERAPY FOR TREATING
HEPATITIS VIRUS INFECTIONS

October 5, 1998

GROUP 1800

OCT 15 1998

RECEIVED

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO Form 1449 (modified) for consideration by the U.S. Patent and Trademark Office in the above-entitled application and to be made of record herein.

Applicants believe that the above Supplemental Information Disclosure Statement is being submitted prior to issuance of the first Office Action. However, in the event any fee is deemed necessary, the Commissioner is hereby authorized to charge any such fee which may be required during the pendency of this application to Account No. 19-1345.

Respectfully submitted,

Charles E. Cohen, Registration No. 34,565
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

CERTIFICATE OF MAILING

I certify that this Supplemental Information Disclosure Statement, PTO Form 1449 and references are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 5th day of October, 1998.

Sabrina D. Loftis

CMG/sdl
Attachments